WO2002002104A1 - Traitement de la dermatite de contact provoquee par urushiol et procede correspondant - Google Patents

Traitement de la dermatite de contact provoquee par urushiol et procede correspondant Download PDF

Info

Publication number
WO2002002104A1
WO2002002104A1 PCT/US2000/018462 US0018462W WO0202104A1 WO 2002002104 A1 WO2002002104 A1 WO 2002002104A1 US 0018462 W US0018462 W US 0018462W WO 0202104 A1 WO0202104 A1 WO 0202104A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
composition
urushiol
contact dermatitis
induced contact
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/018462
Other languages
English (en)
Inventor
William M. Yarbrough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
William M Yarbrough Foundation
Original Assignee
William M Yarbrough Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William M Yarbrough Foundation filed Critical William M Yarbrough Foundation
Priority to AU2000259157A priority Critical patent/AU2000259157A1/en
Publication of WO2002002104A1 publication Critical patent/WO2002002104A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8105—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
    • A61K8/8111—Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants

Definitions

  • the present invention relates to treatments for allergic dermatitis and more particularly, to a treatment for Toxicodendron dermatitis, which results from contact with the Rhus oleoresin urushiol.
  • Urushiol is the toxin responsible for the allergic dermatitis caused by contact with the sap of commonly encountered noxious plants such as poison ivy, poison oak, and poison sumac, and related plants found throughout the world. Urushiol or related chemicals are also found in the Anacardiaceae group, which includes, among others, the lacquer tree of Asia, mango tree, cashew shell oil and in certain nut shells, such as the walnut. The American Academy of Dermatology estimates that there are up to 50 million cases of urushiol induced contact dermatitis annually in the United States alone. No one is sure of the number of world wide annual exposures but some experts estimate that the number could be double that of the United States.
  • urushiol induced contact dermatitis is a world wide problem.
  • urushiols are mixtures of catechols with long, hydrophobic, carbon(alkyl) side chains at the three position of the catechol ring.
  • poison ivy contains predominantly 3-w-pentadececylcatechols (C-15) and poison oak contains predominantly 3-n- heptaecylcatechols (C-17).
  • Urushiol When located inside an unruptured plant leaf, Urushiol is a light, colorless oil. When exposed to oxygen, urushiol easily oxidizes arid, after polymerizing, turns a blackish color.
  • the reaction is the result of exposure to the oleoresin containing the urushiol.
  • the reaction is an allergic eczematous contact dermatitis characterized by redness, swelling, papules, vesicles, bullae, and streaking.
  • Treatment has historically consisted of attempting to remove the oil as quickly after exposure as possible: applying rubbing alcohol, washing affected areas with water, and showering with soap and water. Unfortunately, if the above procedure is not commence within minutes of exposure the regimen will not remove the toxin but may limit its spread. Attempts have been made to find both prophylactic treatments as well as post- exposure treatments. To date, no vaccine has been developed and the prior art treatments are not without shortcomings.
  • One treatment example is seen in U.S.
  • Patent number 5,686,074 to Stewart which teaches and claims a treatment for poison ivy which includes a composition including linseed oil, an astringent, a starch, an essential oil and a citrus oil.
  • linseed oil can cause irritation itself.
  • a second shortcoming of this patent is that it requires that the composition be applied to the affected areas up to twice a day until the rash is gone. The composition provides what appears to be only very temporary palliative relief of poison ivy symptoms and does not appear to alter the course of the malady.
  • Other proposed treatments are seen in U. S.
  • U.S. Patent number 4,663,151 to Waali discloses and claims a prophylactic treatment based upon Aluminum Chlorhydrate.
  • the most significant shortcoming associated with prophylactic treatments is that they are only effective if applied before exposure to the urushiol; an occurrence that rarely takes place.
  • a significant advance in the treatment of poison ivy is seen in an unpatented product sold under the mark Tech-Nu ® and manufactured by Tec Laboratories, Inc. of Albany, Oregon.
  • this product is not without shortcomings.
  • This product was originally developed as a treatment for radiation exposure. It was discovered, however, that the product also provided some relief for poison ivy exposure.
  • the main active ingredient in the Tech-nu® product is Octylphenoxy-polyethoxyethanol.
  • the four octyl groups of this chemical are to large too surround the non polar moieties in the urushiol. Therefore, it only partially matches the polarity of urushiol. Thus, the action of this product renders the urushiol only partially inactive. Since the urushiol remains partially active and continues to cause irritation, only temporary relief is provided and multiple applications are necessary.
  • a treatment which is safe to use It is yet another object of the present invention to provide a treatment for urushiol induced allergic dermatitis which is topical, can be purchased over the counter and is economical.
  • IV. SUMMARY OF THE INVENTION The above objects of the invention are provided for in a topical treatment for urushiol induced contact dermatitis.
  • a method is provided for applying a composition of substances to the effected area, working the composition into the effected area, and removing the composition from the effected area.
  • the composition comprises at least one ethoxylate in combination with Sodium Lauroyl Sarconinate (or "SLS").
  • this combination binds to the available urushiol receptors-i rendering it inactive.
  • the affinity of the receptors for the ethoxylates also appears to cause a release of the urushiol from its epidermal bonds for bonding to the composition.
  • An inert scrubbing agent such as polyethylene beads, can also be included to assist in the release of the urushiol.
  • Acetylated lanolin alcohol, 'sodium lauroyl sarcominate, EDTA, a foam stabilizer, and water can also be added to the composition without effecting performance.
  • urushiol is the toxin responsible for the contact dermatitis caused by poison ivy, poison oak, and other urushiol containing plants.
  • urushiol When housed inside an unruptured plant leaf, urushiol is a light, colorless oil. The leaves are easily-damaged by the slightest contact or even breeze. Therefore, it is rare to find a plant that does not have at least some ruptured leaves.
  • urushiol When exposed to oxygen, urushiol easily oxidizes and, after polymerizing, turns a blackish color. The reaction experienced by most people is the result of exposure to the oleoresin containing the urushiol.
  • the reaction is an allergic eczemato ⁇ s contact dermatitis characterized by redness, swelling, papules, vesicles, bullae, and streaking.
  • Urushiol is the name given to a family catechols having long, hydrophobic, carbon(alkyl) side chains at the three position of the catechol ring.
  • the chemical structure of the urushiol found in the poison ivy plant is:
  • the product has been sold as an industrial hand cleaner and has never heretofore been known to be effective against urushiol toxicity. It has only been promoted as a hand cleaner.
  • Chemical analysis and research by the inventors has revealed that two of the component parts of the Redman product are central to its effectiveness as a treatment for urushiol induced contact dermatitis: an ethoxylate and Sodium Lauroyl Sarconinate.
  • the ethoxylate is a nonylphenel ehtoxylate, Unlike the ethoxylate of the Tech-Nu ® product, the present invention's ethoxylate has the large octyl groups removed.
  • the ethoxylate can "wrap" around the non-polar molecules of the urushiol.
  • the long chain moiety of the present invention's ethoxylate is only four carbons long, as opposed to ten. This feature also assists the ethoxylate in bonding to the urushiol more effectively.
  • the ethoxylate itself is not capable of forming a complete micelle around the urushiol. The inventors have discovered that the addition of Sodium Lauroyl Sarcosinide, the micelle is completed and the urushiol can be cleansed away from the skin. SLS also has a long carbon chain that can surround the non-polar portions of the urushiol.
  • SLS contains a highly polar end that aids in surrounding the polar ends of urushiol and also in the invention's reactivity with water.
  • the combination of the ethoxylate and SLS create a large molecule that contains flexible non-polar groups and soluble polar groups. This permits the inventive composition to quickly and effectively surround the urushiol and then be rinsed away with water, a highly polar substance.
  • the inventors have also discovered that the addition of an inert scrubbing agent improves the action of the inventive composition. The scrubbing agent assists by causing the urushiol to detach from the skin and place it in position for bonding with the active chemical components of the inventive composition.
  • any inert agent will suffice but the inventors believe that poly ethylene beads work best.
  • the beads should be large enough to be effective but not so large as to cause abrasions.
  • the inventors suggest beads in the range of 5 to 50 microns with an average size being approximately 25 microns or 50 mesh.
  • an exact ratio of ethoxylate to SLS is not critical. The only requirement is that the ethoxylate is completely reacted with the SLS, creating a polymer. This will vary with the ethoxylate used, but the inventors have determined that a ratio of ethoxylate-to- SLS of 1.5:2 is preferred.
  • the amount by weight of polyethylene beads can vary according to the grittiness desired.
  • a formula of ethoxylate: SLS .-polyethylene of 40:20:40 is preferred but that formulas of other concentrations are useful.
  • formulas having SLS ranging from 10 to 20 % by weight, ethoxylate ranging from 20 to 40 % by weight, and polyethylene beads from 20 to 50% by weight are reasonable. But again, the formula is not restricted to these ranges, which ranges are presented for example purposes only.
  • a cutting agent that does not chemically react with the composition may be added. The cutting agent makes the overall composition flow more easily, thereby enabling more packaging options such as tubes. The cutting agent must be added only in sufficient amount that it promotes flow but does not effect the action of the cornposition.
  • the composition In use, the composition is applied to an effected area and worked over the area by a scrubbing motion. After sufficient time has elapsed to ensure that the effected area has been adequately exposed to the composition, the composition and bound urushiol are washed away. Experiments have demonstrated that a majority of people need only one treatment to be relieved of itching; however, severe cases may require two treatments approximately eight hours apart.
  • the inventive composition works at varying rates of effectiveness at any time during the rash cycle.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un traitement localisé de la dermatite de contact provoquée par urushiol. Elle concerne un procédé de traitement consistant à appliquer une composition de substances à la zone concernée, à faire pénétrer la composition dans ladite zone et à enlever cette composition de ladite zone. Cette composition contient au moins un éthoxylate combiné à sarconinate de sodium laurylé (SLS). On pense que cette combinaison se fixe aux récepteurs disponibles d'urushiol, les rendant, de ce fait, inactifs. L'affinité de ces récepteurs pour les éthoxylates semble également provoquer le dégagement d'urushiol de ses liaisons épidermiques afin de se fixer à la composition. Cette composition peut également contenir un agent d'épuration inerte, tel que des perles de polyéthylène, permettant de contribuer à la libération d'urushiol. On peut également ajouter à la composition de l'alcool de lanoline acétylé, sarconinate de sodium laurylé, EDTA, un stabilisant de mousse ou de l'eau, sans en restreindre les capacités.
PCT/US2000/018462 1999-07-03 2000-07-06 Traitement de la dermatite de contact provoquee par urushiol et procede correspondant Ceased WO2002002104A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2000259157A AU2000259157A1 (en) 1999-07-03 2000-07-06 Urushiol induced contact dermatitis treatment and method of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34771400A 2000-07-03 2000-07-03
US09/347,714 2000-07-03

Publications (1)

Publication Number Publication Date
WO2002002104A1 true WO2002002104A1 (fr) 2002-01-10

Family

ID=23364920

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/018462 Ceased WO2002002104A1 (fr) 1999-07-03 2000-07-06 Traitement de la dermatite de contact provoquee par urushiol et procede correspondant

Country Status (1)

Country Link
WO (1) WO2002002104A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656017A4 (fr) * 2003-08-12 2008-11-05 William M Yarbrough Foundation Composition pour le traitement lie aux organismes piquants et penetrants et aux parasites, et pour le traitement de l'urticaire, et procede d'utilisation
US11154486B2 (en) 2020-02-14 2021-10-26 William M. Yarbrough Foundation Detergent compositions for washing urushiol and methods of treating urushiol induced contact dermatitis
US11191708B2 (en) 2020-02-17 2021-12-07 William M. Yarbrough Foundation Sodium lauroyl sarcosinate containing detergent compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620527A (en) * 1986-07-16 1997-04-15 The Sterilex Corporation Cleansing and disinfecting method
US5833999A (en) * 1994-10-20 1998-11-10 The Proctor & Gamble Company Personal treatment compositions and /or cosmetic compositions containing enduring perfume
US5888520A (en) * 1996-04-30 1999-03-30 Hydromer, Inc. Composition, barrier film, and method for preventing contact dermatitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620527A (en) * 1986-07-16 1997-04-15 The Sterilex Corporation Cleansing and disinfecting method
US5833999A (en) * 1994-10-20 1998-11-10 The Proctor & Gamble Company Personal treatment compositions and /or cosmetic compositions containing enduring perfume
US5888520A (en) * 1996-04-30 1999-03-30 Hydromer, Inc. Composition, barrier film, and method for preventing contact dermatitis

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656017A4 (fr) * 2003-08-12 2008-11-05 William M Yarbrough Foundation Composition pour le traitement lie aux organismes piquants et penetrants et aux parasites, et pour le traitement de l'urticaire, et procede d'utilisation
US11154486B2 (en) 2020-02-14 2021-10-26 William M. Yarbrough Foundation Detergent compositions for washing urushiol and methods of treating urushiol induced contact dermatitis
US11857666B2 (en) 2020-02-14 2024-01-02 William M. Yarbrough Foundation Detergent compositions for washing urushiol and methods of treating urushiol induced contact dermatitis
US12329843B2 (en) 2020-02-14 2025-06-17 The William Yarbrough Foundation Detergent compositions for washing urushiol and methods of treating urushiol induced contact dermatitis
US11191708B2 (en) 2020-02-17 2021-12-07 William M. Yarbrough Foundation Sodium lauroyl sarcosinate containing detergent compositions
US11951200B2 (en) 2020-02-17 2024-04-09 The William M. Yarbrough Foundation Sodium lauroyl sarcosinate containing detergent compositions
US12263236B1 (en) * 2020-02-17 2025-04-01 The William Yarbrough Foundation Sodium lauroyl sarcosinate containing detergent compositions

Similar Documents

Publication Publication Date Title
US6423746B1 (en) Urushiol induced contact dermatitis and method of use
EP1656128A1 (fr) Traitement de l'acne simple et procede d'utilisation
US10561626B2 (en) Method for treating urushiol induced contact dermatitis
US5756560A (en) Method and composition for promoting improved adhesion to substrates
US20120034314A1 (en) Antiseptic Liquid Formulation, A Method for Its Use, and A Method for Preparing the Formulation
MXPA96003054A (en) A method and a composition to promote improved unahesion to the substrates
WO2003070206A1 (fr) Agent de traitement servant a proteger une fibre animale
US12263236B1 (en) Sodium lauroyl sarcosinate containing detergent compositions
US20250255800A1 (en) Detergent compositions for washing urushiol and methods of treating urushiol induced contact dermatitis
WO2002002104A1 (fr) Traitement de la dermatite de contact provoquee par urushiol et procede correspondant
FR2782923A1 (fr) Procede de transformation d'une composition cosmetique en un film, film obtenu et kit
EP1762227B1 (fr) Compositions, utilisations et kit pour le traitment de la dermatite
CA2078730A1 (fr) Composition pour le traitement des ongles contenant un aminoacide soufre
WO2004052358A1 (fr) Traitement topique des dermatites dues a un contacts avec de l'urushiol, et methodes d'utilisation associees
EP1435901B1 (fr) Compositions de traitement du cheveu et procede et appareil associes
JP2994565B2 (ja) 染着除去剤
EP0621034B1 (fr) Composition contenant des complexes de l'aluminium pour le traitement des brûlures thermiques ou chimiques
WO1993003706A1 (fr) Compositions et procedes pour modifier la couleur des cheveux
CN1318018C (zh) 用于皮肤护理的局部抗氧化剂维生素组合物
US5021455A (en) Solution for neutralizing caustic effects of alkaline cementitious materials on human skin
SU1683752A1 (ru) Крем дл защиты кожи рук от антрациклиновых антибиотиков
RU2006112206A (ru) Композиции для ухода за кожей и способы
WO2012126198A1 (fr) Solution neutralisante des acides et des bases pour la protection contre les brûlures chimiques
FR2704148A1 (fr) Solution physiologique pour le lavage des parties du corps humain ou animal ayant été en contact avec un produit corrosif ou irritant, procédé et concentré pour sa préparation.
HK1068257B (en) Hair treatment compositions and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN JP KP KR NZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP